Edgewise Therapeutics Inc (EWTX)

Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)June 16, 2026 7:00 AM
PR Newswire (US) – No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% – – Consistent and clinically meaningful improvements observed in echocardiogram parameters, biomarkers, symptoms and functional status across obstructive and nonobstructive HCM  –– EDG-7500 administration continued to be generally well tolerated –– Company to host webcast today at 8:30 a.m. Eastern Time –BOULDER, Colo., June 16, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive top-line results from the 12-week Phase 2 Part D CIRRUS-HCM trial of EDG-7500 in obstructive (oHCM) and nonobstructive (nHCM) HCM. EDG-7500 is a novel, oral, selective cardiac sarcomere modulator designed to slow early contraction velocity and improve impaired cardiac relaxation in symptomatic HCM without compromising systolic function. To date, in over 700 echocardiograms performed in healthy adults and patients with HCM, there was no relationship observed between multiple measures of systolic function and concentration of EDG-7500. CIRRUS-HCM is a multi-part (A-D), open label trial of EDG-7500 in patients with oHCM and nHCM. Part D is a 12-week cohort designed to inform a Phase 3 trial. In oHCM, dosing was guided by left ventricular outflow tract gradient (LVOT-G), while in nHCM, dosing was guided by N-terminal pro-B-type natriuretic peptide (NT-proBNP), a key biomarker of heart failure. Patients in both groups received doses ranging from 25 mg to 150 mg. A total of 53 patients (20 with oHCM and 33 with nHCM) completed Part D 12-week study.Results in Patients with oHCM
Patients with oHCM receiving EDG-7500 demonstrated broad and clinically meaningful responses across key measures of hemodynamics, biomarkers, patient-reported health status and functional status. Consistent with previous findings, significant reductions in LVOT-G were observed at rest and post Valsalva, with 90% of patients demonstrating improvement in hemodynamic measures. In a key measure of heart failure severity, 74% of patients achieved either normalization of NT-proBNP levels (defined as

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesJune 3, 2026 4:01 PM
PR Newswire (US) BOULDER, Colo., June 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on May 29, 2026, Edgewise granted inducement stock options to purchase a total of 74,000 shares of Edgewise's common stock to 4 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").    Each inducement stock option has an exercise price of $34.16 per share, which is equal to the closing price of a share of Edgewise common stock on the grant date, and shall vest as follows: 25% of the shares subject to such inducement stock option shall vest on the one year anniversary of the start date of each employee, and an additional one forty-eighth (1/48th) of the shares subject to such inducement stock option shall vest monthly thereafter, subject to the employee's continued service.Each inducement award is subject to the terms of the Inducement Plan and related forms of agreements, and were granted as inducements material to these employees to enter into employment with Edgewise in accordance with Nasdaq Listing Rule 5635(c)(4). About Edgewise Therapeutics Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of symptomatic hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: edgewisetx.com or follow us on LinkedIn and X.This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release. View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-302790649.htmlSOURCE Edgewise Therapeutics Original: Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesApril 1, 2026 8:00 AM
PR Newswire (US)

BOULDER, Colo., April 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on March 31, 2026, Edgewise granted inducement stock options to purchase a total of 72,000 shares of Edgewise's common stock to 4 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").







Each inducement stock option has an exercise price of $32.46 per share, which is equal to the closing price of a share of Edgewise common stock on the grant date, and shall vest as follows: 25% of the shares subject to such inducement stock option shall vest on the one year anniversary of the start date of each employee, and an additional one forty-eighth (1/48th) of the shares subject to such inducement stock option shall vest monthly thereafter, subject to the employee's continued service.Each inducement award is subject to the terms of the Inducement Plan and related forms of agreements, and were granted as inducements material to these employees to enter into employment with Edgewise in accordance with Nasdaq Listing Rule 5635(c)(4). About Edgewise Therapeutics Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of symptomatic hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to edgewisetx.com or follow us on LinkedIn and X.This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.



View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-302730770.htmlSOURCE Edgewise Therapeutics

Original: Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026March 4, 2026 8:00 AM
PR Newswire (US)

BOULDER, Colo., March 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present at the Leerink Global Healthcare Conference on Wednesday, March 11, 2026, at 1:40 p.m. ET.







The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay for a limited time following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.About Edgewise TherapeuticsEdgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of symptomatic hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to edgewisetx.com or follow us on LinkedIn, X, Facebook and Instagram.



View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-present-at-the-leerink-global-healthcare-conference-on-march-11-2026-302699637.htmlSOURCE Edgewise Therapeutics

Original: Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific ConferenceMarch 3, 2026 8:00 AM
PR Newswire (US)

BOULDER, Colo., March 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. The Company will host a lunch forum with experts presenting Becker natural history data and discussing the need for community and definition of care. New sevasemten data in Becker will also be presented at the conference including from the MESA open-label extension trial. The conference will take place at the Hilton Orlando in Orlando, Fla., from March 8–11, 2026.







Details of the Edgewise forum and scientific posters at MDA:Edgewise Lunch Forum Highlighting Becker Natural History, Community Progress, and Multi-Disciplinary Care with Neuromuscular Disease Experts Date: Monday, March 9, 2026, at noon ETTitle: Elevating Becker Outcomes: Unlocking New Insights, Mobilizing Communities, and Redefining Care Presenters: Matthew Wicklund, M.D., FAAN, Professor of Neurology, Vice Chair for Research, Department of Neurology, UT Health San AntonioAbby Bronson, M.B.A., Vice President, Patient Advocacy and External Innovation, EdgewiseAmit Sachdev, M.D., M.S., Associate Chief Medical Officer, MSU Healthcare, Medical Director, Department of Neurology and Assistant Professor, Neuromuscular Medicine, Michigan State UniversityModerator: Roxana Donisa Dreghici, M.D., Vice President, Clinical Development, EdgewiseOnly conference attendees can register for the forum.Scientific PostersTitle: Long-term stabilization of function in Becker: Sevasemten prevented functional decline up to 3.5 years in MESA open-label extension (477LB)
Presenter: Craig M. McDonald, M.D., Distinguished Professor and Chair at the UC Davis Health Department of Physical Medicine and Rehabilitation, and a Principal Investigator in CANYON and GRAND CANYON
Date: Tuesday, March 10, 2026Title: Effects of sevasemten on LVEF and NT-proBNP in adults with Becker muscular dystrophy in CANYON (470LB)
Presenter: Ben Barthel, Ph.D., Edgewise
Date: Monday, March 9, 2026Title: Patient-focused drug development: Understanding the patient experience and meaningful treatment outcomes in Becker muscular dystrophy via interviews (8S)
Presenter: Abby Bronson, Edgewise
Date: Sunday, March 8, 2026Title: Female carriers of BMD and DMD mutations show elevated muscle injury proteins, and muscle loss progression is predicted by plasma ART3 concentration (167M)
Presenter: Luuli Tran, Ph.D., Edgewise
Date: Monday, March 9, 2026Posters will be showcased at various times throughout the day in the Exhibit Hall. The full MDA 2026 Conference program is available at mdaconference.org.The Edgewise presentation and posters will be available on the Edgewise website following the presentations.About Sevasemten
Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage in muscular dystrophies including Becker and Duchenne. Sevasemten presents a novel mechanism of action designed to selectively limit the exaggerated muscle damage caused by the absence or loss of functional dystrophin. Sevasemten has achieved notable regulatory milestones by securing FDA Orphan Drug Designation for the treatment of Becker and Duchenne, Rare Pediatric Disease Designation (RPDD) for the treatment of Duchenne, and Fast Track designations for the treatment of Becker and Duchenne. Further, sevasemten secured the EMA Orphan Drug Designations for the treatment of Becker and Duchenne.For more information on Edgewise's clinical trials, visit the Company's website.About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of symptomatic hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to edgewisetx.com or follow us on LinkedIn, X, Facebook and Instagram.This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.



View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-present-on-sevasemten-for-the-treatment-of-becker-muscular-dystrophy-at-the-2026-mda-clinical-and-scientific-conference-302701734.htmlSOURCE Edgewise Therapeutics

Original: Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesMarch 2, 2026 9:30 AM
PR Newswire (US)

BOULDER, Colo., March 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on February 27, 2026, Edgewise granted inducement stock options to purchase a total of 51,000 shares of Edgewise's common stock to 3 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").







Each inducement stock option has an exercise price of $30.44 per share, which is equal to the closing price of a share of Edgewise common stock on the grant date, and shall vest as follows: 25% of the shares subject to such inducement stock option shall vest on the one year anniversary of the start date of each employee, and an additional one forty-eighth (1/48th) of the shares subject to such inducement stock option shall vest monthly thereafter, subject to the employee's continued service.Each inducement award is subject to the terms of the Inducement Plan and related forms of agreements and were granted as inducements material to these employees to enter into employment with Edgewise in accordance with Nasdaq Listing Rule 5635(c)(4).About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn and X.This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.



View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-302701086.htmlSOURCE Edgewise Therapeutics

Original: Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026February 5, 2026 8:00 AM
PR Newswire (US)

BOULDER, Colo., Feb. 5, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Behrad Derakhshan, Ph.D., Chief Operating Officer, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 3:00 pm ET.







The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.About Edgewise TherapeuticsEdgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn and X.



View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026-on-february-12-2026-302679536.htmlSOURCE Edgewise Therapeutics

Original: Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026

Piper Sandler Maintains Overweight on Edgewise Therapeutics, Raises Price Target to $51

CANYON Phase 2 placebo-controlled trial in adults with Becker : CANYON, the largest interventional Becker trial to date, includes 40 adults and 29 adolescents with a sevasemten treatment period of 12 months. The primary endpoint of CANYON is change in creatine kinase (CK) over the treatment period with additional measures collected, including North Star Ambulatory Assessment (NSAA), 100-meter timed test, biomarkers of muscle damage and MRI. The Company expects to report CANYON data in the fourth quarter of 2024.

Kiwi

New high following presentation
Topline data from CANYON is anticipated in 4Q24

Phase 2 trial in adults with Becker

Kiwi

From IBD ....The biotech company tested its drug, EDG-7500, in healthy volunteers and patients with obstructive hypertrophic cardiomyopathy. In this disease, a genetic mutation causes the heart ventricles to thicken. This limits cardiac function and exercise capacity.

After a single dose, patients showed improved blood flow from the left ventricle. But sometimes drugs can do their job too well, suppressing cardiac function — a measure known as reduced left ventricular ejection fraction, or LVEF. But patients didn't show meaningful reductions in LVEF.. my emphasis


Kiwi

RMB Gr8 data ...especially . Importantly, gradient reduction was achieved without a meaningful change in LVEF
So maybe no REMS limitation
Kiwi

Topline data from CANYON is anticipated in 4Q24

Phase 2 trial in adults with Becker

Kiwi

Sizable sell off despite this again today
RBC Capital Reiterates Outperform on Edgewise Therapeutics, Maintains $32 Price Target

Kiwi

RBC Capital Reiterates Outperform on Edgewise Therapeutics, Maintains $32 Price Target

Kiwi

JPMorgan Raises Price Target on Edgewise Therapeutics to $30 From $27, Maintains Overweight Rating
Kiwi

I used to own CYTK and think I sold it because of this ...from the CYTK trial Core echocardiographic left ventricular ejection fraction (LVEF) was observed to be

Thanks for all the info Kiwi. Been a long busy day so I will have to do some more DD on this one but it appears to be promising. The fact that the drug does not have the ejection fraction problem is important in my books. This could be another CYTK. My one worry is that it has had quite a sunup in 2024 already and hopefully not everything is priced in yet.

Before EWTX there was MYOK in HCM ...bt out at $225 a share .
EWTX hired some MYOK folks after this buyout
https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-to-Acquire-MyoKardia-for-13.1-Billion-in-Cash/default.aspx

Kiwi

Watch for a technical breakout as market anticipates the P1 HCM data
Mavacamten is I think the drug currently approved for HCM ( heart contractibility problems ) . The problem is it lowers ejection fraction ( the pump out movement ) to low for about 20% of the patients so it has a REMS rating limiting its use.
EWTX EDG-5506 works the same way but without the ejection fraction problem

Data due this Qt ( Q3 )

Kiwi

Piper Sandler analyst Yasmeen Rahimi maintains Edgewise Therapeutics ( EWTX ) with a Overweight and maintains $48 price target.

Kiwi

RMB. some HCM P1 data due late Aug / Sept ...
Kiwi

RMB. I think we are due for data from the LYNX trial
, Edgewise Therapeutics expects to report 3-month data from the Phase 2 LYNX trial for EDG-5506 in the second quarter of 2024. The LYNX trial is a Phase 2 dose-ranging study to evaluate the safety and efficacy of EDG-5506 in patients with Duchenne muscular dystrophy (DMD).

New high today

Kiwi

Wedbush Reiterates Outperform on Edgewise Therapeutics, Maintains $26 Price Target

I'm surprised stock didn't do better on recent P 2 data ...which was supposed to " de risk " their program

Kiwi

BOULDER, Colo., February 13, 2024--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDG-5506 for the treatment of Duchenne.
EDG-5506 is an investigational orally administered small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies, including Duchenne and Becker muscular dystrophy (Becker).
The FDA previously granted EDG-5506 Orphan Drug Designation (ODD) for the treatment of Duchenne and Becker, Rare Pediatric Disease Designation (RPDD) for the treatment of Duchenne, and Fast Track designation for the treatment of Becker.
---------------
Kiwi

RMB. for what its worth ...both stocks I mentioned are now "technically " over bought ...so some pull back near term is likely
jmo
Kiwi

RMB. EWTX up 21 % in past week. ( since your post )
VERA ,,,which I think U saw me posting on at the AUPH board ...up 28%
Both I think at 52 wk highs

Usually I find it best to initiate small positions ...follow ..and then if the data still looks good , add on a pullback due to some unrelated event .
Both of these Co's have a lot of data coming out in 2024

Kiwi

EWTX new 52 week high

EWTX new 52 week high

Jonathan C. Fox, M.D., Ph.D., FACC
DIRECTOR
Jonathan C. Fox, M.D., Ph.D., FACC, serves as a member of our board of directors and is the president and chief medical officer for cardiovascular and renal diseases at BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical stage biotechnology company developing novel, genetically targeted therapies. Prior to that, Dr. Fox served as the chief medical officer of MyoKardia, Inc. Additionally, he worked as a consultant at Nigel-Montgomery, LLC, and held various senior R&D positions successively at SmithKline Beecham, Merck Research Laboratories and AstraZeneca. He was also on the faculty of the University of Pennsylvania School of Medicine. Dr. Fox serves on the board at ML BioSolutions and is a trustee of the Lankenau Institute for Medical Research. He is currently an adjunct Professor of Medicine at the Stanford University Cardiovascular Institute. He received his A.B. in biology, his Ph.D. in experimental pathology and his M.D. from the University of Chicago, and completed his training in Internal Medicine and Cardiology at Duke University. Dr. Fox is ABIM Certified in Cardiovascular Diseases and is a Fellow of the American College of Cardiology.


MyoKardia was bt out by BMS
Kiwi

RMB. You might look at TNYA also ...similar space. Ceo is one very smart guy and is backed by the Column group ( smart team )
Early days tho .
EWTX is far further along

BOTH are high speculative ...so.....etc
Kiwi

Kiwi you have peaked my interest in EWTX

The opportunity seems to be here, but I will try to exhibit something I rarely do, namely; patience.

It has risen a bunch in a short time and I hope to pick some up after a bit of a retracement.

EWTX. Best Co I've seen in this area since MYOK ...which was eventually bt out .
Kiwi

Impressive presentation at JPM 2024 . Fast tracked but the earliest they are likely to have an approved drug is early 2026...if all goes well
Kiwi

Looks like we may have hit the bottom lol

Jumped in at $30 today hope we have a good run here

Edgewise Therapeutics, Inc. (NASDAQ: EWTX) gained 87.5% to close at $30.00 after pricing its IPO at $16 per share.

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The Company is principally focused on discovering, developing and commercializing treatments for rare muscle disorders. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The Company's lead candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). The Company's research programs include EDG-6289, EDG-002 and EDG-003.